Impact of Type of Lenvatinib Resistance on Prognosis and Second-Line Regimen in Patients with Virus-Associated HCC
There is a high rate of primary resistance to lenvatinib in patients with HCC and the prognosis for those with primary resistance is poor. TKI combined with PD-1 inhibitors should be preferentially recommended for lenvatinib-resistant patients.
Authors
- Huaxing Ma
- Shi Zuo (ORCID: https://orcid.org/0000-0002-8595-5062)
- Lei Jin (ORCID: https://orcid.org/0000-0002-0752-7628)
- Yijie Zhang (ORCID: https://orcid.org/0000-0002-6184-3963)
Institutions
- Guiyang Medical University (CN)
- Soochow University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2024-08-01
- DOI
- https://doi.org/10.2147/jhc.s476439
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.11
Funders
- Guizhou Science and Technology Department
- Guizhou Medical University